Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases.
The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases.
Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego.
The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe.
Kupando is headquartered in Schoenefeld, Germany. 

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Kupando GmbH

Kupando GmbH's headquarters in Schönefeld, Germany

Johanna Holldack

Wolfram Nothaft

Angelika Leppert

Thomas Dümmler

Roberto Maj

Description

People (3)

Johanna Holldack

Angelika Vlachou

Moritz Beissenhirtz

Jobs